Share: Facebook Twitter LinkedIn
Activity Provided By:

American Academy of CME

Ace the Case: Newly Diagnosed AML: Can Molecular Markers Direct Treatment?

Access Activity

Overview / Abstract:

Knowledge of the key management issues for patients with AML is critical. Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications.


Feb 23, 2024


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME



Credits / Hours




Presenters / Authors / Faculty

Naval G. Daver, MD
Associate Professor
Director, Leukemia Research Alliance
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Annie Lattanzio Hale, MSN, RN, OCN
Oncology Nurse Navigator
Ann B. Barshinger Cancer Institute
Lancaster, PA

Megan May, PharmD, BCOP
Clinical Oncology Pharmacy Specialist
Baptist Health Lexington Cancer Center
Lexington, KY

Sponsors / Supporters / Grant Providers

This educational activity is supported by an educational grant from AbbVie.

Keywords / Search Terms

American Academy of CME acute myeloid leukemia older adults hematology Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map